Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

T Yoshino, J M Cleary, E Van Cutsem, R J Mayer, A Ohtsu, E Shinozaki, A Falcone, K Yamazaki, T Nishina, R Garcia-Carbonero, Y Komatsu, H Baba, G Argilés, A Tsuji, A Sobrero, K Yamaguchi, M Peeters, K Muro, A Zaniboni, N Sugimoto, Y Shimada, Y Tsuji, H S Hochster, T Moriwaki, B Tran, T Esaki, C Hamada, T Tanase, F Benedetti, L Makris, F Yamashita, H-J Lenz, T Yoshino, J M Cleary, E Van Cutsem, R J Mayer, A Ohtsu, E Shinozaki, A Falcone, K Yamazaki, T Nishina, R Garcia-Carbonero, Y Komatsu, H Baba, G Argilés, A Tsuji, A Sobrero, K Yamaguchi, M Peeters, K Muro, A Zaniboni, N Sugimoto, Y Shimada, Y Tsuji, H S Hochster, T Moriwaki, B Tran, T Esaki, C Hamada, T Tanase, F Benedetti, L Makris, F Yamashita, H-J Lenz

Abstract

Background: The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in patients with refractory metastatic colorectal cancer. This post hoc analysis investigated pharmacokinetic data of FTD/TPI exposure and pharmacodynamic markers, such as chemotherapy-induced neutropenia (CIN) and clinical outcomes.

Patients and methods: A total of 210 patients from RECOURSE were enrolled in this substudy. A limited sampling approach was used, with three pharmacokinetic samples drawn on day 12 of cycle 1. Patients were categorized as being above or below the median area under the plasma concentration-time curve (AUC) for FTD and TPI. We conducted a post hoc analysis using the entire RECOURSE population to determine the correlations between CIN and clinical outcome. We then carried out a similar analysis on the J003 trial to validate the results.

Results: In the RECOURSE subset, patients in the high FTD AUC group had a significantly increased CIN risk. Analyses of the entire population demonstrated that FTD/TPI-treated patients with CIN of any grade in cycles 1 and 2 had significantly longer median overall survival (OS) and progression-free survival (PFS) than patients who did not develop CIN and patients in the placebo group. Patients who required an FTD/TPI treatment delay had increased OS and PFS versus those in the placebo group and those who did not develop CIN. Similar results were obtained in the J003 cohort.

Conclusions: In RECOURSE, patients with higher FTD drug exposure had an increased CIN risk. FTD/TPI-treated patients who developed CIN had improved OS and PFS versus those in the placebo group and those who did not develop CIN. Similar findings were reported in the J003 cohort, thus validating the RECOURSE results. The occurrence of CIN may be a useful predictor of treatment outcomes for FTD/TPI-treated patients. CLINICALTRIALS.

Gov identifier: NCT01607957 (RECOURSE).

Japan pharmaceutical information center number: JapicCTI-090880 (J003).

Keywords: FTD/TPI; J003; RECOURSE; chemotherapy-induced neutropenia; metastatic colorectal cancer.

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1.
Figure 1.
RECOURSE: Kaplan–Meier estimates of overall survival (OS) and progression-free survival (PFS) in the pharmacokinetic/pharmacodynamic (PK/PD) population according to high and low area under the curve (AUC) of trifluridine (FTD) (OS: A; PFS: C) or tipiracil (TPI) (OS: B; PFS: D) or placebo treatment.
Figure 2.
Figure 2.
RECOURSE: Kaplan–Meier estimates of overall survival (OS) in cycles 1 and 2 according to chemotherapy-induced neutropenia (CIN) grade versus placebo (A) and no CIN (B).
Figure 3.
Figure 3.
J003: Kaplan–Meier estimates of overall survival (OS) in cycles 1 and 2 according to chemotherapy-induced neutropenia (CIN) grade.

References

    1. Emura T, Suzuki N, Fujioka A, et al. Potentiation of the antitumor activity of α, α, α-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. Int J Oncol. 2005;27:449–455.
    1. Cleary JM, Rosen LS, Yoshida K, et al. A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone. Invest New Drugs. 2017;35:189–197.
    1. Yoshino T, Mizunuma N, Yamazaki K, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012;13:993–1001.
    1. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909–1919.
    1. Hamauchi S, Yamazaki K, Masuishi T, et al. Neutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102. Clin Colorectal Cancer. 2017;16:51–57.
    1. Kasi PM, Kotani D, Cecchini M, et al. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer. 2016;16:467.
    1. Nishina T, Yoshino T, Shinozaki E, et al. Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030). J Clin Oncol. 2016;34(15 Suppl):Abstract no. 3557.
    1. Cremolini C, Rossini D, Martinelli E, et al. Trifluridine/tipiracil (TAS-102) in refractory metastatic colorectal cancer: a multicenter register in the frame of the Italian compassionate use program. Oncologist. 2018;23:1178–1187.
    1. National Cancer Institute. Common Terminology Criteria for Adverse Events v4.03 (CTCAE), 2010. Available at . Accessed November 1, 2018.
    1. Doi T, Ohtsu A, Yoshino T, et al. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer. 2012;107:429–434.
    1. Overman MJ, Kopetz S, Varadhachary G, et al. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008;26:794–799.
    1. Tan X, Wen Q, Wang R, Chen Z. Chemotherapy-induced neutropenia and the prognosis of colorectal cancer: a meta-analysis of cohort studies. Expert Rev Anticancer Ther. 2017;17:1077–1085.
    1. Kimura M, Usami E, Iwai M, et al. Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer under oral trifluridine-tipiracil (TAS-102) chemotherapy. Pharmazie. 2017;72:49–52.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever